GlassScriptPhysician profile
Randi L Rigsby
NPI 1750617007
$7,548.40
in general payments reported to CMS, 2019-2025
38 companies · $1,756 in 2025
The $1,756 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,111 · 2022: $1,204 · 2023: $1,785 · 2024: $1,693 · 2025: $1,756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,233.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $874.78 | 2021-2025 | Ozempic, Wegovy, Saxenda |
| Astrazeneca Pharmaceuticals LP | $844.00 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $741.92 | 2021-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $624.70 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $601.53 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Abbvie INC. | $440.57 | 2021-2025 | |
| Pfizer INC. | $432.77 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $361.18 | 2021-2025 | |
| Astellas Pharma US INC | $285.81 | 2021-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $285.40 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Mylan Specialty L.P. | $276.27 | 2021-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.81 | 2021-2025 | Jardiance, Spiriva Respimat |
| Preventric Diagnostics, INC. | $241.81 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $187.56 | 2021-2024 | Austedo Xr, Austedo |
| Sanofi-Aventis U.S. LLC | $119.46 | 2021-2023 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $117.36 | 2021-2024 | Injectafer |
| Janssen Pharmaceuticals, INC | $109.20 | 2021-2023 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $87.31 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.88 | 2022-2025 | |
| Exact Sciences Corporation | $61.77 | 2023-2025 | Cologuard Collection Kit |
| Phadia US INC. | $56.88 | 2022-2023 | Immunocap |
| Ethicon US, LLC | $40.64 | 2021 | |
| Merck Sharp & Dohme LLC | $39.68 | 2024 | Gardasil 9, Gardasil, Vaxneuvance |
| Almatica Pharma LLC | $36.30 | 2024-2025 | Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $36.04 | 2021-2025 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $31.29 | 2021 | |
| Verona Pharma, INC. | $29.18 | 2025 | Ohtuvayre |
| Itamar Medical INC | $28.82 | 2025 | Watchpatone |
| Amarin Pharma, INC. | $27.76 | 2021 | |
| Boston Scientific Corporation | $27.61 | 2023 | Watchman Access System |
| Otsuka America Pharmaceutical, INC. | $23.52 | 2025 | Rexulti |
| Sanofi Pasteur INC. | $20.83 | 2025 | |
| Dexcom, INC. | $19.54 | 2024 | Dexcom G6 Transmitter |
| Smith+Nephew, INC. | $18.08 | 2022 | |
| Neurocrine Biosciences, INC. | $16.65 | 2025 | |
| Insulet Corporation | $14.50 | 2024 | Omnipod |
| Phathom Pharmaceuticals, INC. | $14.03 | 2024 | Voquezna |
| Electromed, INC. | $11.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randi Rigsby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.